|
US4737456A
(en)
|
1985-05-09 |
1988-04-12 |
Syntex (U.S.A.) Inc. |
Reducing interference in ligand-receptor binding assays
|
|
US4676980A
(en)
|
1985-09-23 |
1987-06-30 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Target specific cross-linked heteroantibodies
|
|
US5959177A
(en)
|
1989-10-27 |
1999-09-28 |
The Scripps Research Institute |
Transgenic plants expressing assembled secretory antibodies
|
|
CA2116774C
(en)
|
1991-09-19 |
2003-11-11 |
Paul J. Carter |
Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
|
|
US5789199A
(en)
|
1994-11-03 |
1998-08-04 |
Genentech, Inc. |
Process for bacterial production of polypeptides
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US5840523A
(en)
|
1995-03-01 |
1998-11-24 |
Genetech, Inc. |
Methods and compositions for secretion of heterologous polypeptides
|
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
|
DK0979281T3
(da)
|
1997-05-02 |
2005-11-21 |
Genentech Inc |
Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
US6040498A
(en)
|
1998-08-11 |
2000-03-21 |
North Caroline State University |
Genetically engineered duckweed
|
|
US7125978B1
(en)
|
1999-10-04 |
2006-10-24 |
Medicago Inc. |
Promoter for regulating expression of foreign genes
|
|
PT1222292E
(pt)
|
1999-10-04 |
2005-11-30 |
Medicago Inc |
Metodo para regulacao da transcricao de genes exogenos na presenca de azoto
|
|
AU2001247616B2
(en)
|
2000-04-11 |
2007-06-14 |
Genentech, Inc. |
Multivalent antibodies and uses therefor
|
|
JP4336498B2
(ja)
|
2000-12-12 |
2009-09-30 |
メディミューン，エルエルシー |
延長した半減期を有する分子ならびにその組成物および用途
|
|
HRP20050986A2
(en)
*
|
2002-08-19 |
2006-11-30 |
Abgenix |
Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof
|
|
WO2004035752A2
(en)
|
2002-10-15 |
2004-04-29 |
Protein Design Labs, Inc. |
ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
|
|
US7871607B2
(en)
|
2003-03-05 |
2011-01-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
|
|
US20070148170A1
(en)
|
2005-10-03 |
2007-06-28 |
Desjarlais John R |
Fc Variants With Optimized Fc Receptor Binding Properties
|
|
EP1673395A1
(en)
|
2003-10-15 |
2006-06-28 |
PDL BioPharma, Inc. |
Alteration of fc-fusion protein serum half-lives by mutagenesis of positions 250, 314 and/or 428 of the heavy chain constant region of ig
|
|
EP2385069A3
(en)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
|
US20050260711A1
(en)
|
2004-03-30 |
2005-11-24 |
Deepshikha Datta |
Modulating pH-sensitive binding using non-natural amino acids
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
EP3342782B1
(en)
|
2004-07-15 |
2022-08-17 |
Xencor, Inc. |
Optimized fc variants
|
|
WO2006031370A2
(en)
|
2004-08-19 |
2006-03-23 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
US20060115485A1
(en)
|
2004-10-29 |
2006-06-01 |
Medimmune, Inc. |
Methods of preventing and treating RSV infections and related conditions
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
BRPI0517837A
(pt)
|
2004-11-12 |
2008-10-21 |
Xencor Inc |
variantes fc com ligação alterada a fcrn
|
|
US20090298195A1
(en)
|
2005-01-05 |
2009-12-03 |
F-Star Biotechnologische Forschungs-Und Entwicklun Gseges M.B.H. |
Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
|
|
WO2006105338A2
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc VARIANTS WITH OPTIMIZED PROPERTIES
|
|
CN101198698B
(zh)
|
2005-03-31 |
2014-03-19 |
中外制药株式会社 |
通过调节多肽缔合制备多肽的方法
|
|
PE20061444A1
(es)
*
|
2005-05-19 |
2007-01-15 |
Centocor Inc |
Anticuerpo anti-mcp-1, composiciones, metodos y usos
|
|
WO2007110205A2
(en)
|
2006-03-24 |
2007-10-04 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
|
WO2007147901A1
(en)
|
2006-06-22 |
2007-12-27 |
Novo Nordisk A/S |
Production of bispecific antibodies
|
|
PL2383297T3
(pl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc |
Zoptymalizowane przeciwciała ukierunkowane na CD19
|
|
US20080044455A1
(en)
|
2006-08-21 |
2008-02-21 |
Chaim Welczer |
Tonsillitus Treatment
|
|
DK2059533T3
(da)
|
2006-08-30 |
2013-02-25 |
Genentech Inc |
Multispecifikke antistoffer
|
|
EP2097451A2
(en)
*
|
2006-12-22 |
2009-09-09 |
Ablynx N.V. |
Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
JP2011517548A
(ja)
*
|
2007-06-29 |
2011-06-16 |
セントコア・オーソ・バイオテツク・インコーポレーテツド |
抗ｍｃｐ−１抗体、組成物、方法及び使用
|
|
EP3415529B1
(en)
|
2007-09-26 |
2020-11-04 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
|
AU2008345242B2
(en)
|
2007-10-31 |
2014-02-27 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
EP3663318A1
(en)
|
2008-01-07 |
2020-06-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
|
EP2275443B1
(en)
|
2008-04-11 |
2015-12-02 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
|
KR101834999B1
(ko)
|
2008-10-14 |
2018-03-06 |
제넨테크, 인크. |
이뮤노글로불린 변이체 및 그의 용도
|
|
EP2233500A1
(en)
|
2009-03-20 |
2010-09-29 |
LFB Biotechnologies |
Optimized Fc variants
|
|
BRPI1014089A2
(pt)
|
2009-04-02 |
2016-04-19 |
Roche Glycart Ag |
anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples
|
|
PT2417156E
(pt)
|
2009-04-07 |
2015-04-29 |
Roche Glycart Ag |
Anticorpos trivalentes, biespecíficos
|
|
AU2010245011B2
(en)
|
2009-04-27 |
2015-09-03 |
Oncomed Pharmaceuticals, Inc. |
Method for making heteromultimeric molecules
|
|
AU2010252284A1
(en)
|
2009-05-27 |
2011-11-17 |
F. Hoffmann-La Roche Ag |
Tri- or tetraspecific antibodies
|
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
|
MX2012003396A
(es)
|
2009-09-16 |
2012-04-10 |
Genentech Inc |
Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
|
|
SI2519543T1
(sl)
|
2009-12-29 |
2016-08-31 |
Emergent Product Development Seattle, Llc |
Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
|
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
|
|
EP2569337A1
(en)
|
2010-05-14 |
2013-03-20 |
Rinat Neuroscience Corp. |
Heterodimeric proteins and methods for producing and purifying them
|
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
|
PL2635607T3
(pl)
|
2010-11-05 |
2020-05-18 |
Zymeworks Inc. |
Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
|
|
TWI654204B
(zh)
|
2010-11-30 |
2019-03-21 |
Chugai Seiyaku Kabushiki Kaisha |
具有鈣依存性的抗原結合能力之抗體
|
|
WO2012132067A1
(ja)
|
2011-03-30 |
2012-10-04 |
中外製薬株式会社 |
抗原結合分子の血漿中滞留性と免疫原性を改変する方法
|
|
CA2827923C
(en)
|
2011-02-25 |
2021-11-23 |
Chugai Seiyaku Kabushiki Kaisha |
Fc.gamma.riib-specific fc antibody
|
|
WO2012122011A2
(en)
|
2011-03-04 |
2012-09-13 |
Glaxosmithkline Llc |
Amino-quinolines as kinase inhibitors
|
|
MY171038A
(en)
|
2011-08-23 |
2019-09-23 |
Roche Glycart Ag |
Bispecific antigen binding molecules
|
|
SG11201401102VA
(en)
|
2011-09-30 |
2014-09-26 |
Chugai Pharmaceutical Co Ltd |
Ion concentration-dependent binding molecule library
|
|
WO2013047752A1
(ja)
|
2011-09-30 |
2013-04-04 |
中外製薬株式会社 |
抗原の消失を促進する抗原結合分子
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
CA3233142A1
(en)
|
2011-11-30 |
2013-06-06 |
Chugai Seiyaku Kabushiki Kaisha |
Drug containing carrier into cell for forming immune complex
|
|
PT2794905T
(pt)
|
2011-12-20 |
2020-06-30 |
Medimmune Llc |
Polipéptidos modificados para estrutura de anticorpos bispecíficos
|
|
WO2013125667A1
(ja)
|
2012-02-24 |
2013-08-29 |
中外製薬株式会社 |
FcγRIIBを介して抗原の消失を促進する抗原結合分子
|
|
SG11201405830VA
(en)
*
|
2012-03-27 |
2014-10-30 |
Genentech Inc |
Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
|
|
DK2838918T3
(da)
|
2012-04-20 |
2019-08-12 |
Merus Nv |
Fremgangsmåder og midler til fremstilling af heterodimere ig-lignende molekyler
|
|
SG10202006507XA
(en)
|
2012-05-30 |
2020-08-28 |
Chugai Pharmaceutical Co Ltd |
Target-tissue-specific antigen-binding molecule
|
|
EP3892638A1
(en)
|
2012-05-30 |
2021-10-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule for eliminating aggregated antigens
|
|
SG11201500873XA
(en)
|
2012-08-24 |
2015-04-29 |
Chugai Pharmaceutical Co Ltd |
Fcgriib-specific fc region variant
|
|
EP2970508A4
(en)
|
2013-03-15 |
2016-12-14 |
Permeon Biologics Inc |
GENETICALLY MODIFIED LOADING ANTIBODIES OR ENHANCED ENHANCEMENT ENHANCEMENT TARGETING PROTEIN COMPOSITIONS AND METHODS OF USE
|
|
CA2912443A1
(en)
*
|
2013-05-23 |
2014-11-27 |
Shire Human Genetic Therapies, Inc. |
Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma
|
|
JP7325166B2
(ja)
|
2013-12-20 |
2023-08-14 |
ジェネンテック， インコーポレイテッド |
二重特異性抗体
|
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
|
CN106573986A
(zh)
|
2014-07-29 |
2017-04-19 |
豪夫迈·罗氏有限公司 |
多特异性抗体
|
|
NZ730607A
(en)
|
2014-12-19 |
2022-07-01 |
Chugai Pharmaceutical Co Ltd |
Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
|
|
WO2016125495A1
(en)
|
2015-02-05 |
2016-08-11 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
|
EP3286227A2
(en)
|
2015-04-24 |
2018-02-28 |
F. Hoffmann-La Roche AG |
Multispecific antigen-binding proteins
|
|
CN108271372B
(zh)
|
2015-09-18 |
2021-07-09 |
中外制药株式会社 |
Il-8-结合抗体及其应用
|
|
CN112243444A
(zh)
|
2018-06-08 |
2021-01-19 |
豪夫迈·罗氏有限公司 |
具有减少的翻译后修饰的肽接头
|
|
WO2021122733A1
(en)
*
|
2019-12-18 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|